Encompass Health Corporation

NYSE:EHC

Medical - Care Facilities

Healthcare
$134.93 -1.95%

-$1.95 today

Market cap
$13.24B
Beta
0.59
P/E (TTM)
15.9
EPS (TTM)
$6.14
Dividend yield
0.76%
52W Low $92.77High $127.99

Volume 0.84M

Average 0.92M

EHC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Encompass Health CorporationNYSE: EHC

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How EHC compares with its peers on the latest reported figures

  • EHC's LTM Jun 2026 research & development of $0 is the highest of the 9 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for EHC, versus a peer median of 0.0%.
EHC Competitors Peer median
Research & Development for EHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EHCEncompass Health CorporationLTM Jun 2026$0 ——0.0%
ENSGThe Ensign Group, Inc.LTM Jun 2026$0 ——0.0%
PACSPACS Group, Inc.LTM Jun 2026$0 ——0.0%
CHEChemed CorporationLTM Jun 2026$0 ——0.0%
OPCHOption Care Health, Inc.LTM Sep 2026$0 ——0.0%
NHCNational HealthCare CorporationLTM Sep 2026$0 ——0.0%
AVAHAveanna Healthcare Holdings Inc.LTM Oct 2026$0 ——0.0%
ADUSAddus HomeCare CorporationLTM Jun 2026$0 ——0.0%
PNTGThe Pennant Group, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding EHC) $0——0.0%

Competitors are the stored peer set for EHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.01B4.35B4.8B5.37B5.94B
Cost of Revenue2.31B2.6B2.82B3.14B3.37B
Gross Profit1.7B1.75B1.98B2.23B2.56B
Gross Margin42.4%40.3%41.3%41.6%43.2%
Research & Development00000
Selling, General & Admin228.5M209M258M266.5M295.2M
Operating Expenses1.04B1.12B1.25B1.37B1.51B
Depreciation & Amortization219.6M243.6M273.9M299.6M327.9M
EBITDA888.9M870.1M1.02B1.19B1.4B
EBITDA Margin22.1%20.0%21.3%22.1%23.7%
Operating Income659.4M630.2M731.8M864.5M1.05B
Operating Margin16.4%14.5%15.2%16.1%17.7%
Interest Income00000
Interest Expense164.3M175.7M143.5M137.4M123.2M
Other Income / Expenses(154.4M)(179.4M)(124.6M)(114.9M)(100.1M)
Income Before Tax505M450.8M607.2M749.6M953M
Pre-Tax Margin12.6%10.4%12.6%14.0%16.1%
Income Tax Expense101.9M100.1M132.2M150.2M192.9M
Net Income412.2M271M352M455.7M566.2M
Net Margin10.3%6.2%7.3%8.5%9.5%
EPS (Basic)4.152.723.544.535.62
EPS (Diluted)4.112.703.474.465.54
Weighted Avg Shares99M99.2M99.5M99.9M100.5M
Weighted Avg Shares (Diluted)100.2M100.4M101.3M102.2M102.2M

Encompass Health Corporation

NYSE:EHC

Intrinsic Alpha fair value

Locked

Current Price

$134.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.